The estimated Net Worth of Matthew Geller is at least $1.61 Million dollars as of 24 May 2011. Matthew Geller owns over 7,700 units of Biospecifics Technologies stock worth over $885,300 and over the last 15 years Matthew sold BSTC stock worth over $724,739.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Matthew Geller BSTC stock SEC Form 4 insiders trading
Matthew has made over 4 trades of the Biospecifics Technologies stock since 2010, according to the Form 4 filled with the SEC. Most recently Matthew sold 10,000 units of BSTC stock worth $244,000 on 6 June 2011.
The largest trade Matthew's ever made was exercising 30,000 units of Biospecifics Technologies stock on 15 April 2010 worth over $570,000. On average, Matthew trades about 12,000 units every 83 days since 2009. As of 24 May 2011 Matthew still owns at least 10,000 units of Biospecifics Technologies stock.
You can see the complete history of Matthew Geller stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Matthew Geller's mailing address?
Matthew's mailing address filed with the SEC is 248 CENTRAL PARK WEST, , NEW YORK, NY, 10024.
Insiders trading at Biospecifics Technologies
Over the last 33 years, insiders at Biospecifics Technologies have traded over $67,860,045 worth of Biospecifics Technologies stock and bought 7,761,661 units worth $656,708,120 . The most active insiders traders include Capital Management, Llc Kol..., International Plc Endo, and Max Link. On average, Biospecifics Technologies executives and independent directors trade stock every 73 days with the average trade being worth of $6,538,649. The most recent stock trade was executed by International Plc Endo on 2 December 2020, trading 7,344,955 units of BSTC stock currently worth $650,028,518.
What does Biospecifics Technologies's logo look like?
Complete history of Matthew Geller stock trades at Biospecifics Technologies
Biospecifics Technologies executives and stock owners
Biospecifics Technologies executives and other stock owners filed with the SEC include:
-
Jennifer Chao,
Independent Chairman of the Board -
Michael Schamroth,
Independent Director -
Paul Gitman,
Independent Director -
Mark Wegman,
Director -
Toby Wegman,
Director -
Sarah McCabe,
Stern Investor Relations -
Michael Sherman,
Independent Director -
Corey Fishman,
Independent Director -
Alex Monteith,
Senior Vice President and Chief Business Officer -
Patrick Hutchison,
Chief Financial Officer -
Joseph Truitt,
Chief Executive Officer, Director -
Jeffrey Kenneth Vogel,
-
Jyrki Mattila,
Director -
Thomas Wegman,
President -
Of Edwin H. Wegman Estate,
10% owner -
Patrick M Caldwell,
Principal Financial Officer -
Partners Lp Bio,
10% owner -
Albert Horcher,
-
Lawrence Dobroff,
CFO -
Max Link,
Director -
Henry Morgan,
Director -
George M Gould,
Director -
Matthew Geller,
Director -
Capital Management, Llc Kol...,
-
Capital Management, Llcra C...,
-
Capital Management, Llcaldr...,
-
Capital Management, Llc Kol...,
-
Capital Management, Llcra C...,
-
J Kevin Buchi,
Chief Executive Officer -
International Plc Endo,
10% owner